Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
In five randomised groups, 249 Chinese adults with a BMI of 28-40 kg/mv received once-weekly subcutaneous injections of HRS9531 (1.0 mg, 3.0 mg, 4.5 mg, and 6.0 mg) or a placebo for six months
Key Metrics & Financial Highlights Metric Value Year 1 Revenue $600-800K Year 3 Revenue $10-18M LTV:CAC Ratio 9.8:1 Gross Margin 66% Target Exit Valuation $60-100M (Years 3-4) Initial Capital Required $50-75K MARKET OPPORTUNITY Market Size & Growth Current market: 12 million Americans on GLP-1 medications 2026 projection: 15+ million users Growth rate: 25% annually Patient spend: $900-1,500/month per patient on medication alone Search intent: 50,000+ monthly searches for GLP-1 nutrition solutions Total Addressable Market 12M users 30% willing to pay = 3.6M addressable customers 3.6M $65/month 12 months = $2.8B annual TAM Conservative penetration of 5-10% = $140-280M realistic market Year 1 serviceable market: 1-2% = $28-56M The Problem GLP-1 patients face three critical, interconnected problems: 1
The primary objective of the titration schedule is to maximize weight loss while minimizing gastrointestinal side effects
10.1097/CLD.0000000000000202 127 ShabilM.KhatibM
Further analysis revealed that the DEGs, particularly those genes within the PPAR signaling pathway with upregulated expression, such as angiopoietin-like 4 ( ANGPTL4 ), CD36 , FATP1 , fatty acid transport protein 4 ( FATP4 ), and perilipin 2 ( PLIN2 ) in the leg muscles of caged versus free-range Lueyang black-boned chickens, are associated with IMF deposition (Table 1) [56]
US$ 22.65
US$ 29.30
US$ 24.37
US$ 28.87
US$ 23.22
US$ 28.61
US$ 27.31
US$ 21.78
